期刊
MARINE LIFE SCIENCE & TECHNOLOGY
卷 5, 期 2, 页码 196-210出版社
SPRINGERNATURE
DOI: 10.1007/s42995-023-00168-z
关键词
NASH; AMPK; Inflammation; Lipid metabolism; Fibrosis; Marine drug
Non-alcoholic steatohepatitis (NASH) is a leading cause of cirrhosis and hepatocellular carcinoma. A marine natural compound, candidusin A (CHNQD-0803), has been identified as a potent AMPK activator and a potential therapeutic candidate for NASH treatment.
Non-alcoholic steatohepatitis (NASH) is a primary cause of cirrhosis and hepatocellular carcinoma. Unfortunately, there is no approved drug treatment for NASH. AMP-activated kinase (AMPK) is an important metabolic sensor and whole-body regulator. It has been proposed that AMPK activators could be used for treating metabolic diseases such as obesity, type 2 diabetes and NASH. In this study, we screened a marine natural compound library by monitoring AMPK activity and found a potent AMPK activator, candidusin A (CHNQD-0803). Further studies showed that CHNQD-0803 directly binds recombinant AMPK with a K-D value of 4.728 x 10(-8) M and activates AMPK at both molecular and intracellular levels. We then investigated the roles and mechanisms of CHNQD-0803 in PA-induced fat deposition, LPS-stimulated inflammation, TGF-beta-induced fibrosis cell models and the MCD-induced mouse model of NASH. The results showed that CHNQD-0803 inhibited the expression of adipogenesis genes and reduced fat deposition, negatively regulated the NF-kappa B-TNF alpha inflammatory axis to suppress inflammation, and ameliorated liver injury and fibrosis. These data indicate that CHNQD-0803 as an AMPK activator is a novel potential therapeutic candidate for NASH treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据